While islet cell transplants allow some diabetics to forgo daily insulin injections, those people have to take immunosuppressive drugs in order to keep the cells from being rejected. A new implant, ...
Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...
Company to Proceed with Phase 2 Development Program for Islatravir Subdermal Implant “We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset ...
Little-known emerging biopharmaceutical company Vivani Medical (NASDAQ:VANI) saw its market value increase dramatically on Wednesday. Catapulting sentiment was the company’s weight-loss solution, ...
Wirelessly rechargeable brain implants could make it easier for researchers to control individual neurons in rats using pulses of lights. Optogenetics is a research tool in neuroscience that uses ...
That’s based on the 2024 subdermal implant service fee of $93.41. Indiana’s Medicaid program reimbursed nearly 40,000 live births in 2022, according to the analysis, but a fraction of patients are ...
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase 1 study evaluating the safety, tolerability and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback